Genespire Welcomes New CEO Karen Aiach-Pignet
Genespire is thrilled to announce that Karen Aiach-Pignet has been appointed as the new Chief Executive Officer. This important move underscores Genespire's dedication to leading the way in in-vivo lentiviral gene therapy, particularly for pediatric patients facing genetic disorders.
The Importance of Karen's Appointment
With an impressive background in gene therapy, Karen brings extensive knowledge to her new position. She previously founded and led Lysogene, a pioneer in the industry. Under her leadership, Lysogene advanced an adeno-associated virus (AAV) vector therapy designed for patients with Sanfilippo Type A, a rare neurodegenerative condition. She successfully launched an international Phase 3 clinical trial and forged partnerships that bolstered Lysogene's standing on the Euronext Stock Exchange.
Focus on Advancing GENE202
Karen steps into her role at Genespire during a crucial period, as the company gears up to introduce its lead candidate, GENE202, which is targeting methylmalonic acidemia (MMA). This serious genetic disorder disrupts the body’s ability to process amino acids and fats and usually shows up in infancy, leading to significant health challenges. Currently, there are no disease-modifying treatments available, making Genespire's innovative strategy all the more essential.
Vision and Commitment
Expressing her vision, Karen stated her resolve to improve the lives of patients battling metabolic diseases. She said, "Leading Genespire with the mission to develop safe and effective therapies for those in need is a tremendous honor. I’m committed to leveraging our unique ISLV technology, alongside our devoted team and investors, to drive this company toward success."
Recognizing Past Leadership
Joern Aldag, Chairman of Genespire, also shared his thoughts on this transition, expressing appreciation for Dr. Julia Berretta, the former CEO, for her guidance over the years. He acknowledged the impressive achievements of the Genespire team and highlighted the significance of Karen’s vast experience in the fast-evolving field of gene therapies, especially for rare diseases and pediatric patients.
Karen's Achievements and Background
Karen's career features significant contributions to gene therapy. She is a founding member of the International Rare Diseases Research Consortium, has been part of the Pediatric Committee at the European Medicines Agency, and served on the French Ethical Review Board. Moreover, she has been actively involved with several non-profit organizations dedicated to advocacy and research for rare diseases, underscoring her commitment to the community.
Educational Background
Recently, Karen has focused on Digital Health at Harvard Business School, and her educational qualifications include a degree from ESSEC Business School as well as an Economics major from the Institut d’Études Européennes at University Paris 8. This combination of practical insight and academic knowledge perfectly equips her to lead Genespire into a new era of innovation.
About Genespire
Established in 2020, Genespire is focused on creating off-the-shelf gene therapies that utilize immune shielded lentiviral vectors (ISLVs) for intravenous use. This technology offers a long-lasting therapeutic effect straight from the patient's liver, with the initial focus on inherited metabolic disorders that have urgent medical needs. Located in Milan, Italy, Genespire originated as a spin-off from SR-Tiget, a notable research institute that specializes in cell and gene therapy.
Frequently Asked Questions
What position has Karen Aiach-Pignet been appointed to at Genespire?
Karen Aiach-Pignet is now the Chief Executive Officer at Genespire.
What does Genespire focus on in the biotechnology sector?
Genespire is centered on developing off-the-shelf gene therapies, mainly for pediatric patients facing genetic disorders through the use of immune shielded lentiviral vectors.
What condition is GENE202 developed to treat?
GENE202 is aimed at treating methylmalonic acidemia (MMA), a severe genetic disorder that impacts metabolism.
What experience does Karen Aiach-Pignet have in gene therapy?
Karen has a wealth of experience in gene therapy, having founded and led Lysogene, and is recognized for her pioneering efforts in treatments for rare diseases.
Where is Genespire headquartered?
Genespire is based in Milan, Italy, and operates as a spin-off from the SR-Tiget research institute.
